We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

35 hedge funds and large institutions have $4.82M invested in Lumos Pharma, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

3% less funds holding

Funds holding: 36 → 35 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

21% less capital invested

Capital invested by funds: $6.14M → $4.82M (-$1.32M)

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAG
Private Advisor Group
New Jersey
+$36.2K
2
AI
Atria Investments
North Carolina
+$27.9K
3
Citadel Advisors
Citadel Advisors
Florida
+$14.1K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$8.68K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.09K

Top Sellers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
-$222K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$90K
3
Two Sigma Investments
Two Sigma Investments
New York
-$51.3K
4
UBS Group
UBS Group
Switzerland
-$10.5K
5
Renaissance Technologies
Renaissance Technologies
New York
-$5.68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$963K -$1.47K -570 -0.1%
Goldman Sachs
2
Goldman Sachs
New York
$943K -$3 -1 -0%
Vanguard Group
3
Vanguard Group
Pennsylvania
$566K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$501K -$5.68K -2,200 -1%
AI
5
Acuitas Investments
Washington
$328K +$1.93K +746 +0.5%
JFG
6
Jefferies Financial Group
New York
$280K – – –
LPC
7
Lion Point Capital
New York
$211K – – –
GWM
8
Greenwich Wealth Management
Connecticut
$177K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$118K +$8.09K +3,131 +7%
BlackRock
10
BlackRock
New York
$95.4K – – –
Millennium Management
11
Millennium Management
New York
$85.9K -$1.45K -561 -1%
PAG
12
Private Advisor Group
New Jersey
$69.6K +$36.2K +14,000 +87%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$68.6K -$77 -30 -0.1%
BCM
14
Bridgeway Capital Management
Texas
$64.1K – – –
MAM
15
Marquette Asset Management
Minnesota
$59.8K – – –
Envestnet Asset Management
16
Envestnet Asset Management
Illinois
$45.2K +$8.68K +3,360 +21%
Two Sigma Investments
17
Two Sigma Investments
New York
$44K -$51.3K -19,872 -51%
Citadel Advisors
18
Citadel Advisors
Florida
$43.5K +$14.1K +5,459 +41%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$27.5K – – –
WAOI
20
Wealth Advisors of Iowa
Iowa
$27.1K – – –
State Street
21
State Street
Massachusetts
$26.1K – – –
KFI
22
Key Financial Inc
Pennsylvania
$25.4K – – –
AI
23
Atria Investments
North Carolina
$25.1K +$27.9K +10,803 New
PAG
24
Paladin Advisory Group
Iowa
$9.93K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$8.31K +$2.3K +891 +33%
1
2

LUMO Hedge Fund Activity: Q2 2024 in Review

35 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2024, worth a combined $4.82M — down 21% from $6.14M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of LUMO and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.

The largest buyer was Private Advisor Group, adding an estimated $36.2K. The largest seller was Blackstone Inc, exiting entirely with an estimated $222K sold.

  • 35 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2024, down from 36 in Q1 2024.
  • Funds reported $4.82M of Lumos Pharma, Inc. Common Stock stock for Q2 2024, down 21% quarter-over-quarter.
  • 4 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2024 and 5 closed out, a net change of -1 holder.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2024 was Private Advisor Group, an estimated $36.2K added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q2 2024 was Blackstone Inc, an estimated $222K sold.

Based on aggregated 13F filings for Q2 2024.